SCB-2019

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 20211. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization. SCB-2019 is being funded by CEPI as part of COVAX and has received advanced purchase orders from GAVI for 400 million doses, with production to begin in 2021.

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization. SCB-2019 is being funded by CEPI as part of COVAX and has received advanced purchase orders from GAVI for 400 million doses, with production to begin in 2021.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1317111474 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “SCB-2019” revision 1317111474 · retrieved 2026-10-20 publication date (×1) · confidence 0.95 revision URL